• Verteporfin: Illuminating New Pathways in Translational Rese

  2026-07-22

  This article examines Verteporfin’s dual mechanisms—light-activated photodynamic therapy and light-independent autophagy inhibition—through the lens of surface ectoderm commitment, regulatory network modulation, and translational research. Drawing from cutting-edge findings on YAP-TEAD’s control of super-enhancer networks, we provide mechanistic insights, protocol guidance, and a perspective on Verteporfin’s role in next-generation regenerative medicine.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Axis

  2026-07-22

  This study uncovers gramine’s novel role in suppressing triple-negative breast cancer (TNBC) by inducing ferroptosis through the CUL3–MTDH axis. The findings provide mechanistic insight into ferroptosis regulation and highlight gramine’s promise as a targeted therapeutic approach for aggressive breast cancers.

• SHC-1 Inhibition Modulates CFTR Membrane Abundance in Epithe

  2026-07-21

  This study elucidates how SHC-1-mediated signaling regulates plasma membrane CFTR abundance across epithelial models, revealing a conserved pathway and highlighting model-specific nuances. The findings refine mechanistic understanding of CFTR trafficking, informing experimental design in cystic fibrosis and secretory diarrhea research.

• JSH-23: Precision NF-κB Inhibitor for Inflammation Research

  2026-07-21

  JSH-23 is a selective NF-κB inhibitor that empowers researchers to dissect inflammatory signaling with unprecedented specificity. Its unique mechanism—blocking p65 nuclear translocation without interfering with IκB degradation—makes it ideal for advanced inflammation models and cytokine regulation studies.

• Ruxolitinib Phosphate: Applied JAK/STAT Modulation in Cancer

  2026-07-20

  Ruxolitinib phosphate (INCB018424) enables precise JAK/STAT pathway inhibition, advancing both autoimmune and cancer model workflows with robust experimental reproducibility. Explore stepwise protocols, troubleshooting strategies, and the latest mechanistic insights—anchored by a landmark study linking JAK/STAT suppression to mitochondrial dynamics in aggressive thyroid cancer.

• Silver Nanoparticles Trigger Liver Ferroptosis in Zebrafish

  2026-07-20

  This study identifies ferroptosis as a key driver of liver inflammation following silver nanoparticle exposure in zebrafish, pinpointing pivotal gene regulators and metabolic disruptions. These findings clarify mechanistic links between nanomaterial toxicity, iron-dependent cell death, and metabolic disease pathways.

• Ruxolitinib (INCB018424): Benchmarks in JAK1/2 Inhibition Re

  2026-07-19

  Ruxolitinib (INCB018424) is a highly selective JAK1/2 inhibitor, widely used to interrogate myeloproliferative disorder mechanisms and immune modulation. This article details its mechanism, performance benchmarks, and best-practice integration in research workflows.

• HRR Gene Expression Predicts PARP Inhibitor Response in MPM

  2026-07-18

  Borchert et al. (2019) demonstrate that gene expression profiling of the homologous recombination repair (HRR) pathway can identify malignant pleural mesothelioma (MPM) subgroups susceptible to PARP inhibitor therapy. Their findings suggest that HRR defects, particularly BAP1 mutations, may guide precision treatment strategies beyond standard chemotherapy.

• FOXM1–ERα ceRNA Networks in Female Lung Adenocarcinoma: Insi

  2026-07-17

  The reference study uncovers a novel FOXM1–estrogen receptor alpha (ERα) competitive endogenous RNA (ceRNA) network driving female lung adenocarcinoma (LUAD) progression. By integrating transcriptomic analyses, molecular validation, and immunotherapy response profiling, the work provides mechanistic and biomarker advances with clear implications for ERα-focused cancer research.

• Diminazene Aceturate: Bridging Parasitology and Mitochondria

  2026-07-17

  This article examines Diminazene Aceturate’s evolving role, from a gold-standard antiparasitic to a validated pharmacological tool for ACE2 activation and mitochondrial biogenesis studies in sepsis-induced cardiomyopathy. Integrating mechanistic insights, protocol guidance, and translational context, it provides strategic frameworks for researchers advancing from bench to bedside.

• JSH-23 (SKU B1645): Optimizing NF-κB Inhibition in Inflammat

  2026-07-16

  This article provides an evidence-driven guide for researchers using JSH-23 (SKU B1645) as an NF-κB inhibitor in inflammation research. Through scenario-based Q&A, it addresses practical challenges in assay design, data interpretation, and reagent selection, grounding best practices in published data and validated protocols. Explore how JSH-23 enhances workflow reproducibility and experimental clarity.

• Y-27632 Dihydrochloride: Precision ROCK Inhibition in Patien

  2026-07-16

  Explore how Y-27632 dihydrochloride, a potent ROCK inhibitor, advances disease modeling with patient-derived iPSCs and enhances stem cell viability. This in-depth article uniquely bridges psychiatric disorder research and cytoskeletal signaling for next-generation personalized assays.

• LC–MS/MS Reveals Conversion Pathways of a Novel GS-441524 Pr

  2026-07-15

  This study introduces a novel prodrug of GS-441524 (NGP-1) with enhanced oral bioavailability and applies a new LC–MS/MS method to map its conversion to the active antiviral metabolite in vitro and in vivo. The findings clarify the absorption, metabolic routes, and pharmacokinetics of NGP-1, offering actionable insights for antiviral nucleoside analog development, especially in the context of SARS-CoV-2.

• Angiotensin II in Inflammation: Beyond Vascular Remodeling

  2026-07-15

  Explore how Angiotensin II drives inflammation and macrophage polarization in cardiovascular research. This article offers new insights, protocol guidance, and practical assay wisdom for harnessing Angiotensin II in advanced hypertension and vascular injury models.

• Human iPSC-Derived Sensory Neurons Model HSV-1 Latency and R

  2026-07-14

  This study establishes a robust protocol for differentiating human inducible pluripotent stem cells into sensory neurons capable of supporting latent infection and reactivation by herpes simplex virus 1 (HSV-1). The resulting platform enables scalable, human-specific investigations into HSV-1 latency, advancing research beyond animal models and facilitating the study of neuron-intrinsic mechanisms and therapeutic interventions.

15356 records 1/1024 page Next 12345 下5页 Last page